Werewolf Therapeutics, Inc.
NASDAQ:HOWLBiotechnology
+$0.06 today
- Market cap
- $50.06M
- Beta
- 0.29
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$0.71
Volume 1.85M
Average 5.09M
Returns on capital
Werewolf Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-245.2%
avg -83.0%
ROIC
-173.4%
avg -58.1%
ROA
-87.6%
avg -41.7%
Analysis
ROA is currently the strongest return metric at -87.6% versus its period average of -41.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Daniel J. Hicklin | Founder, CEO, President & Director | USD 645.56K | 62 | 185.65K | 0.38% |
Jonathan Owen | Senior VP, General Counsel & Secretary | — | — | — | — |
Michael Urban | VP of Finance, Corporate Controller & Principal Financial Officer | — | 45 | — | — |
Compensation is shown in the reported currency; data updated Oct 19, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jan 2, 2025.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
112
$4.37M
Net Transaction Value
−$4.37M
Net selling
Most Active
EVNIN LUKE
70 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jul 7, 26Jul 7, 2026 | EVNIN LUKE Indirect | Sell | $33.3K$33,302.99 |
| Jul 6, 26Jul 6, 2026 | EVNIN LUKE Indirect | Sell | $11.4K$11,446.40 |
| Jun 29, 26Jun 29, 2026 | EVNIN LUKE Indirect | Sell | $47.1K$47,125.20 |
| Jun 17, 26Jun 17, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Sell | $136.2K$136,225.60 |
| Jun 17, 26Jun 17, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Sell | $9.7K$9,693.25 |
| Jun 16, 26Jun 16, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Sell | $51.7K$51,683.82 |
| Jun 16, 26Jun 16, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Sell | $3.7K$3,677.43 |
| Jun 15, 26Jun 15, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Sell | $46.9K$46,884.24 |
| Jun 15, 26Jun 15, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Sell | $3.3K$3,336.06 |
| Jun 12, 26Jun 12, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Sell | $63.6K$63,647.60 |
1–10 of 112
Summary
Insiders reported 0 buys worth $0.00 and 112 sells worth $4.37M over the last 12 months. That adds up to net selling of $4.37M. EVNIN LUKE was the most active insider with 70 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Werewolf Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about HOWL's management, answered from reported figures.
Who manages HOWL?
Werewolf Therapeutics, Inc. (HOWL) lists 3 active executives. The top listed executive is Daniel J. Hicklin, Founder, CEO, President & Director.
Are HOWL insiders buying or selling?
Recent insider activity shows net selling of $5.39M.
Continue the stock analysis
Jump to another research area for this company.